X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DIVIS LABORATORIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DIVIS LABORATORIES PFIZER/
DIVIS LABORATORIES
 
P/E (TTM) x 32.9 33.3 98.8% View Chart
P/BV x 4.9 5.4 90.6% View Chart
Dividend Yield % 0.8 0.9 84.3%  

Financials

 PFIZER   DIVIS LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-17
DIVIS LABORATORIES
Mar-17
PFIZER/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,0551,222 168.2%   
Low Rs1,651784 210.6%   
Sales per share (Unadj.) Rs429.8153.1 280.7%  
Earnings per share (Unadj.) Rs73.639.9 184.3%  
Cash flow per share (Unadj.) Rs87.444.6 195.9%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %1.11.0 108.3%  
Book value per share (Unadj.) Rs528.7201.8 262.0%  
Shares outstanding (eoy) m45.75265.47 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.36.6 65.8%   
Avg P/E ratio x25.225.1 100.3%  
P/CF ratio (eoy) x21.222.5 94.3%  
Price / Book Value ratio x3.55.0 70.5%  
Dividend payout %27.225.0 108.5%   
Avg Mkt Cap Rs m84,777266,266 31.8%   
No. of employees `0002.89.7 29.2%   
Total wages/salary Rs m3,0394,687 64.8%   
Avg. sales/employee Rs Th6,925.94,175.0 165.9%   
Avg. wages/employee Rs Th1,070.4481.5 222.3%   
Avg. net profit/employee Rs Th1,186.31,089.3 108.9%   
INCOME DATA
Net Sales Rs m19,66340,643 48.4%  
Other income Rs m1,012749 135.1%   
Total revenues Rs m20,67441,392 49.9%   
Gross profit Rs m3,49114,460 24.1%  
Depreciation Rs m6291,233 51.0%   
Interest Rs m1023 42.5%   
Profit before tax Rs m3,86413,953 27.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,8013,349 53.8%   
Profit after tax Rs m3,36810,604 31.8%  
Gross profit margin %17.835.6 49.9%  
Effective tax rate %46.624.0 194.1%   
Net profit margin %17.126.1 65.6%  
BALANCE SHEET DATA
Current assets Rs m20,78940,105 51.8%   
Current liabilities Rs m7,8706,595 119.3%   
Net working cap to sales %65.782.5 79.7%  
Current ratio x2.66.1 43.4%  
Inventory Days Days60119 50.4%  
Debtors Days Days2281 27.8%  
Net fixed assets Rs m9,17519,995 45.9%   
Share capital Rs m458531 86.2%   
"Free" reserves Rs m23,73153,043 44.7%   
Net worth Rs m24,18953,574 45.2%   
Long term debt Rs m250-   
Total assets Rs m32,70661,585 53.1%  
Interest coverage x403.5618.4 65.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.7 91.1%   
Return on assets %10.317.3 59.8%  
Return on equity %13.919.8 70.3%  
Return on capital %21.426.1 82.0%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m6335,384 0.2%   
Fx outflow Rs m4,06710,399 39.1%   
Net fx Rs m-4,00424,985 -16.0%   
CASH FLOW
From Operations Rs m3,28811,493 28.6%  
From Investments Rs m-2,496-11,372 22.0%  
From Financial Activity Rs m-826-93 887.1%  
Net Cashflow Rs m-3528 -121.8%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 4.9 19.0 25.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.2 137.8%  
Shareholders   85,207 31,796 268.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   BIOCON LTD  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 19, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS